BeiGene
BGNE
#992
Rank
A$31.31 B
Marketcap
$283.09
Share price
1.55%
Change (1 day)
3.93%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$26.31. In 2022 the company made an earnings per share (EPS) of -$30.62 a decrease over its 2021 EPS that were of -$24.05.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-18.3%
2022-$30.6227.35%
2021-$24.05-19.96%
2020-$30.0420.81%
2019-$24.8731.52%
2018-$18.91417.57%
2017-$3.65-37.16%
2016-$5.81158.95%
2015-$2.25

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.58-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA